Expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 in hepatic stellate cells during rat hepatic fibrosis and its intervention by IL-10

Wei-Da Zheng, Li-Juan Zhang, Mei-Na Shi, Zhi-Xin Chen, Yun-Xin Chen, Yue-Hong Huang, Xiao-Zhong Wang

We report the expression of matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in hepatic stellate cells (HSCs) during rat hepatic fibrosis and its intervention by IL-10.

INTRODUCTION

Hepatic fibrosis is a common pathological change resulting from various chronic hepatic injuries characterized by an increase of extracellular matrix (ECM) deposition in the Disse’s space and the imbalance between synthesis and degradation of ECM[1,2]. There is an evidence that liver fibrosis is a potentially reversible process involving effective ECM degradation[3,4].

Hepatic stellate cells (HSCs) play a central role in the pathogenesis of liver fibrosis, a key feature of which is their ability to regulate matrix degradation in the liver[5]. Following liver injury, these cells proliferate and are activated to a profibrogenic myofibroblastic phenotype. In addition to increasing matrix protein synthesis, HSCs express a wide range of matrix metalloproteinases (MMPs) and specific tissue inhibitor of metalloproteinases (TIMPs). MMPs and TIMPs may play a significant role in hepatic fibrosis[6].

In the present study, rat hepatic fibrosis model was established, HSCs were isolated and the expression of MMP-2 and TIMP-1 in HSCs was determined to investigate their possible roles during CCl4-induced hepatic fibrogenesis in rats and the effect of interleukin-10 (IL-10) on this change in vivo.

MATERIALS AND METHODS

Establishment of models

Sixty clean male Sprague-Dawley rats weighing 200-300 g (provided by Shanghai Experimental Animal Center) were divided randomly into three groups. The control group (group N) included 8 rats, the CCl4 group (group C) included 28 rats and the IL-10 group (group I) included 24 rats, respectively. All the rats were bred under routine conditions (room temperature, 22±2 °C; humidity, 55±5%; light, 12 h...
per day; free access to water and food). The rats of group N were injected intraperitoneally with saline 2 mL/kg, twice a week. The rats of group C and group I were injected intraperitoneally with 50% CCl₄ (dissolved in castor oil) 2 mL/kg, twice a week. From the third week, the rats of group I were injected intraperitoneally with IL-10 4 μg/kg (dissolved in saline) 20 min before they were injected with CCl₄. All injections were given twice a week until the rats were killed with their body weight determined before each injection. At the beginning of the 7th and 11th wk, two rats from each group were selected randomly for histological examination, five rats from each group were selected randomly for isolating HSCs.

**Histological examination**

In the 7th and 11th wk, two rats in each group were killed to collect liver samples. The liver tissues were fixed in 40 g/L formaldehyde and embedded with paraffin. Sections were stained with HE and examined under a light microscope.

**Hepatic stellate cell extraction**

In the 7th and 11th wk, five rats in each group were used to isolate HSCs. Isolation and identification of HSC were described previously[7]. Briefly, the rat liver was perfused via portal vein with 0.02% pronase E (Merck) and 0.025% type IV collagenase (Sigma). Cell suspension was centrifuged via portal vein with 0.02% pronase E (Merck) and 0.025% type IV collagenase (Sigma). Cell suspension was centrifuged by 11% Nycodenz (Sigma) density gradient to isolate HSC. Cell suspension was centrifuged at 37°C in an 6% fetal calf serum. HSCs were incubated at 37°C in an atmosphere of 50 mL/L CO₂, most of HSCs attached to the dishes 72 h after primary culture. Then the 96-well plates were washed twice with 0.1 mol/L PBS and fixed with poly-formaldehyde at 4°C overnight. The following procedures were performed according to the instructions of streptavidin/peroxidase (S-P) kit (Beijing Zhongshan Company). The dilution of goat anti-rat MMP-2 and TIMP-1 monoclonal antibody (Beijing Zhongshan Company) was 1:300. Briefly, cells were washed with PBS, incubated with bovine serum albumin in PBS, reacted with primary antibody dissolved in PBS, washed again and incubated with peroxidase-conjugated secondary antibody, washed again and reacted for 20 min with S-P. A brown reaction product was developed by incubation with a buffer containing 3,3-diaminobenzidine tetrahydrochloride (DAB). Results of histological examination and HSC isolation were obvious with lots of mononuclear cells and unusual septa and inflammatory infiltrates were seen (Figure 1E).

**Electrophoresis and semi-quantitative analysis**

The PCR products were run on 2% agarose gel electrophoresis and visualized with ethidium bromide staining. The expected product sizes were 604 bp of MMP-2, 310 bp of TIMP-1 and visualized with ethidium bromide staining. The expected product sizes were 604 bp of MMP-2, 310 bp of TIMP-1. The PCR products were run on 2% agarose gel electrophoresis and visualized with ethidium bromide staining. The expected product sizes were 604 bp of MMP-2, 310 bp of TIMP-1. The PCR products were run on 2% agarose gel electrophoresis and visualized with ethidium bromide staining. The expected product sizes were 604 bp of MMP-2, 310 bp of TIMP-1. The PCR products were run on 2% agarose gel electrophoresis and visualized with ethidium bromide staining. The expected product sizes were 604 bp of MMP-2, 310 bp of TIMP-1. The PCR products were run on 2% agarose gel electrophoresis and visualized with ethidium bromide staining. The expected product sizes were 604 bp of MMP-2, 310 bp of TIMP-1. The PCR products were run on 2% agarose gel electrophoresis and visualized with ethidium bromide staining. The expected product sizes were 604 bp of MMP-2, 310 bp of TIMP-1. The PCR products were run on 2% agarose gel electrophoresis and visualized with ethidium bromide staining. The expected product sizes were 604 bp of MMP-2, 310 bp of TIMP-1. The PCR products were run on 2% agarose gel electrophoresis and visualized with ethidium bromide staining. The expected product sizes were 604 bp of MMP-2, 310 bp of TIMP-1. The PCR products were run on 2% agarose gel electrophoresis and visualized with ethidium bromide staining. The expected product sizes were 604 bp of MMP-2, 310 bp of TIMP-1.

**RESULTS**

**Results of histological examination and HSC isolation**

Specimens from group N showed normal structure of hepatic lobules (Figure 1A). Liver fibrosis became remarkable during the treatment with CCl₄. In the 7th wk, specimens from group C showed that hepatic lobular structure was destroyed completely, steatosis and ballooning degeneration were obvious with lots of mononuclear cells and unusual neutrophils surrounding the centrilobular veins and fibrotic septa, the collagen fibers increased and began to extend to the parenchyma (Figure 1B). Only a few inflammatory cells infiltrated around centrilobular veins without evident changes of lobular structure in group I (Figure 1C). In the 11th wk, complete fibrous septa were seen and pseudolobular structures were also present occasionally in group C (Figure 1D). In group I, normal lobular structure was present and less fibrotic septa and inflammatory infiltrates were seen (Figure 1E).
The results illustrated that fibrogenesis of group I was much less severe than that of group C. A total of $2.45 \times 10^7$ cells per rat were harvested. Cell vitality checked by trypan blue exclusion was higher than 95%. The mean purity of freshly isolated HSC was higher than 95% identified by the expression of desmin (Figure 2).

**Immunoreactivities of MMP-2 and TIMP-1 in three groups**

MMP-2 and TIMP-1 positive expressions were localized in cytoplasm and cell membrane of HSC in all groups by immunocytochemistry. In group N, the expression signals of MMP-2 and TIMP-1 were weak. In the 7th wk, the size of HSC in group C and group I was a little larger than that in group N. The number and length of pseudopodia, the expression signals of MMP-2 and TIMP-1 in group C were stronger than those in group I (Figure 3). In the 11th wk, cell phenotype in group I was a little smaller than that in the 7th wk. The expression signals of MMP-2 in group C decreased obviously compared to those in the 7th wk. Though limited by the number of samples, the expression of TIMP-1 increased obviously with the development of hepatic fibrosis, and decreased after treatment with IL-10; however, the expression of MMP-2 increased in the earlier phase of hepatic fibrosis and decreased after treatment with IL-10.

**Relative amount of MMP-2 and TIMP-1 mRNA in hepatic stellate cells**

In the 7th wk, MMP-2 and TIMP-1 mRNA increased obviously in group C compared with that in group N ($P<0.01$), and decreased significantly after treatment with IL-10 ($P<0.01$). In the 11th wk, MMP-2 mRNA in group I was still lower than that in group C ($P<0.01$), but both dropped compared with that in the 7th wk ($P<0.01$). TIMP-1 mRNA in group I was still lower than that in group C ($P<0.01$) and group I ($P<0.05$) compared with that in the 7th wk (Tables 1, 2 and Figure 4).

**Table 1** Expression of MMP-2 mRNA in HSC (mean±SD)

| Week | $n$ | Group N     | Group C     | Group I     |
|------|----|-------------|-------------|-------------|
| 7    | 5  | 0.073±0.006 | 0.288±0.025 | 0.145±0.004 |
| 11   | 5  | 0.085±0.004 | 0.116±0.006 | 0.080±0.009 |

[$^aP<0.01$ vs group N; $^bP<0.01$ vs group C; $^cP<0.01$ vs 7 wk.]

**Table 2** Expression of TIMP-1 mRNA in HSC (mean±SD)

| Week | $n$ | Group N     | Group C     | Group I     |
|------|----|-------------|-------------|-------------|
| 7    | 5  | 0.968±0.026 | 1.517±0.050 | 1.188±0.025 |
| 11   | 5  | 0.980±0.021 | 2.198±0.042 | 0.964±0.026 |

[$^aP<0.01$ vs group N; $^bP<0.01$ vs group C; $^cP<0.05$, $^dP<0.01$ vs 7 wk.]

---

**Figure 1** Effect of IL-10 on liver histological change in rats with hepatic fibrosis (HE×100). A: Rat liver in group N; B: Rat liver in group C in the 7th wk; C: Rat liver in group I in the 7th wk; D: Rat liver in group C in the 11th wk; E: Rat liver in group I in the 11th wk.

**Figure 2** Desmin expression of HSC cultured for five days by immunochemistry (SP×100).
DISCUSSION
Liver fibrosis is traditionally considered as a progressive pathological process involving multiple cellular and molecular events that lead to deposition of excess matrix proteins in the extracellular space. When this process is combined with ineffective regeneration and repair, there is increasing distortion of the normal liver architecture, and the end result is cirrhosis[8,9].

Current evidence indicates that liver fibrosis is dynamic and can be bidirectional (involving progression and regression); this pathological process involves major changes in the regulation of matrix degradation[10].

In the extracellular space, matrix degradation occurs predominantly as a consequence of the action of a family of enzymes known as MMPs. MMPs are secreted from cells into the extracellular space as proenzymes, which are then activated by a number of specific, usually cell surface-associated cleavage mechanisms. The activated enzymes are in turn inhibited by a family of tissue inhibitors of metalloproteinases (TIMP-1 to -4). By this combination of mechanisms, ECM degradation is closely regulated, which prevents inadvertent tissue damage[11].

HSCs situated in the perisinusoidal Disse’s space play an essential role in liver fibrosis. In normal liver, HSCs are nonfibrogenic cells containing an abundant amount of vitamin A. After chronic liver injury, HSCs proliferate, lose their vitamin A, and transform to \( \alpha \)-SMA-positive myofibroblastic cells that are the major source of collagens, glycoproteins, and proteoglycans accumulated in the fibrotic liver. A variety of growth factors and inflammatory cytokines produced by Kupffer cells, hepatocytes, and infiltrating leukocytes in injured livers induce HSC proliferation or matrix synthesis[12,13].

When cultured for several days on plates, HSCs from normal livers undergo activation remarkably similar to that occurring in vivo after liver injury[14].

IL-10 is an important immunoregulatory cytokine produced by many cell populations. Its main biological function is to limit and terminate inflammatory responses and regulate differentiation and proliferation of immune cells such as T cells, B cells, natural killer cells, and granulocytes[15-18]. IL-10 plays a role in inflammatory, malignant and autoimmune diseases and recombinant human IL-10 has been produced and tested in clinical trials, suggesting that IL-10 may become a new therapeutic target[19].
The knock-out experiments (IL-10/mice) indicated that endogenous IL-10 actually relieves CCl_4-induced fibrosis[22,33]. Similar results have been reported by Nelson[23], but its mechanism remains obscure.

MMPs are able to degrade a wide variety ECM and play a pivotal role in regulating ECM composition. MMP-2 plays an important role in regulating basement membranes as it degrades several of its components including collagen IV, laminin, and fibronectin[23,24]. Our studies showed that compared with normal liver, expression of MMP-2 mRNA was increased several folds in CCl_4-induced liver fibrosis in rats. The change promoted further degradation of the normal liver basement membranes, leading to increased activation and proliferation of HSC and synthesis of type I collagen. This positive feedback loop would theoretically promote the progression of liver fibrosis. The regulation of MMP-2 is not clear. Cytokine TGF-β1 has variable effects on MMP-2 expression and can promote synthesis and activation of MMP-2[23,24], and inflammatory cytokines upregulate the expression of MMP-2 during the earlier stage of liver fibrosis[27,30].

Furthermore, the present study showed that the level of MMP-2 decreased in the 11th wk compared with that in the 7th wk in hepatic fibrosis model group. Possibly, the metabolism of collagen could slow down in the later phase of hepatic fibrosis, and the negative feedback loop could degrade the expression of MMP-2. On the other hand, with the development of hepatic fibrosis, the increased TIMPs inhibit the secretion and activation of MMPs including MMP-2. In contrast to the other authors[26], our study showed weak expression in HSC isolated from normal group. Zhang et al established CCl_4-induced hepatic fibrosis model and IL-10 intervention model and reported that IL-10 can down-regulate the level of cytokines like TGF-β1, TNF-α and IL-6. Chen et al[30], investigated rat HSC cultured in vitro and found that IL-10 inhibits the expression of TGF-β1 and FGF, suggesting that IL-10 might inhibit the expression of MMP-2 indirectly by suppressing the expression of cytokines and growth factors.

The activities of MMPs are inhibited by TIMPs[31]. Four members of the TIMP family have been characterized so far, and designated as TIMP-1, TIMP-2, TIMP-3 and TIMP-4. TIMP-1 and TIMP-2 are capable of inhibiting the activities of all known MMPs and play a key role in maintaining the balance between ECM deposition and degradation in different physiological processes, including liver fibrosis development[32]. In the liver, TIMP-1 and TIMP-2 have been identified and TIMP-1 plays a more important role in the pathological process of liver fibrosis than TIMP-2[20,23,33,34].

In the present study, TIMP-1 expression in HSC was markedly up-regulated in group C and correlated with the histological degree of liver fibrosis. Because the expression of MMP-1 remains unchanged in liver at any stage of fibrosis[33], the strong expression of TIMP-1 inhibits the degeneration of collagen by MMP-1, thus promoting the deposition of ECM. The continuous deposition of collagen fibers in the liver finally results in hepatic fibrosis. The result suggests that TIMP-1 plays a pivotal role in liver fibrosis development. Whether TIMP-1 has other pathways to promote hepatic fibrosis is still unknown; further studies are needed to elucidate the mechanism.

Antifibrotics can be used to inhibit TIMP-1 expression. In the present study, we observed the effect of recombinant IL-10 on HSC expression of TIMP-1 in vivo. Our results indicate that IL-10 reduces collagen deposition, which may result from a decrease in TIMP-1 synthesis by HSCs. Because TIMP-1 and MMP-2 have a similar source, IL-10 might inhibit the expression of TIMP-1 indirectly also by suppressing the expression of cytokines and growth factors such as TGF-β1, TNF-α and IL-6.

In summary, MMP-2 expression increases in the early stage of hepatic fibrosis and TIMP-1 expression increases in the whole process of hepatic fibrosis. MMP-2 and TIMP-1 play an important role in liver fibrosis, IL-10 exhibits an antifibrogenic effect by suppressing MMP-2 and TIMP-1 expression.

REFERENCES

1. Liu HL, Li XH, Wang DY, Yang SP. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 expression in fibrotic rat liver. World J Gastroenterol 2000; 6: 881-884
2. Vaillant B, Chiaramonte MG, Cheever AW, Soloway PD, Wynn TA. Regulation of hepatic fibrosis and extracellular matrix genes by the th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J Immunol 2001; 167: 7017-7026
3. Haemel P, Couvelard A, O'Toole D, Ratoius A, Sauvanet A, Flejou JF, Degott C, Belghiti J, Bernades P, Valla D, Ruszniewski P, Levy P. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001; 344: 418-423
4. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, Hovell C, Arthur MJ. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatocellular cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998; 102: 538-549
5. McCrudden R, Iredale JP. Liver fibrosis, the hepatic stellate cell and tissue inhibitors of metalloproteinases. Histol Histopathol 2000; 15: 1159-1168
6. Arthur MJ. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2000; 279: G245-G249
7. Zheng WD, Wang XZ, Zhang LJ, Shi MN. A simple in isolating rat hepatocellular stellate cells. Fujian Yike Daxue Xuebao 2004; 38: 71-73
8. Alcolado R, Arthur MJ, Iredale JP. Pathogenesis of liver fibrosis. Clin Sci (Lond) 1997; 92: 103-112
9. Friedman SL. Molecular mechanisms of hepatic fibrosis and principles of therapy. J Gastroenterol 1997; 32: 424-430
10. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatocellular stellate cells. Semin Liver Dis 2001; 21: 373-384
11. Bode W, Fernandez-Catalan C, Grams F, Gomis-Ruth FX, Nagase H, Tschesche H, Maskos K. Insights into MMP-TIMP interactions. Ann N Y Acad Sci 1999; 878: 73-91
12. Arthur MJ, Mann DA, Iredale JP. Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. J Gastroenterol Hepatol 1998; 13 Suppl: S33-S38
13. Gressner AM. Transdifferentiation of hepatocellular stellate cells (Ito cells) to myofibroblasts: a key event in hepatic fibrogenesis. Kidney Int Suppl 1996; 54: S39-S45
14. Burt AD. Pathobiology of hepatic stellate cells. J Gastroenterol 1999; 34: 299-304
15. Oberholzer A, Oberholzer C, Moldawer LL. Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med 2002;
Effect of transforming growth factor-beta1, interleukin-6, and interferon-gamma on the expression of type I collagen, heat shock protein 47, matrix metalloproteinase (MMP)-1 and MMP-2 by fibroblasts from normal gingiva and hereditary gingival fibromatosis. J Periodontol 2003; 24: 296-306

Marra F, Romanelli RG, Giannini C, Falili P, Pastacaldi S, Arrighi MC, Pinzani M, Laffi G, Montalto P, Gentilini P. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology 1999; 29: 140-148

Milani S, Herbst H, Schuppan D, Grappone C, Pellegrini G, Pinzani M, Casini A, Calabro A, Ciancio G, Stefanini F. Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol 1994; 144: 528-537

Chen YX, Wang XZ, Weng SG, Chen ZX, Huang YH, Zhang LJ. Effects of IL-10 and PDGF on expression of TGF-$\beta_1$ at hepatic stellate cells. Zhongxiyi Jiehe Ganbing Zazhi 2002; 12: 343-345

Gomez DE, Alonso DF, Yoshiji H, Thorgersson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111-122

Benyon RC, Iredale JP, Goddard S, Winwood PJ, Arthur MJ. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 1996; 110: 821-831

Yoshiji H, Kuriyama S, Miyamoto Y, Thorgersson UP, Gomez DE, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, Thorgersson SS, Fukui H. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 2000; 32: 1248-1254

Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Yanase K, Namisaki T, Imazu H, Fukui H. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 2002; 36: 850-860

Iredale JP, Goddard S, Murphy G, Benyon RC, Arthur MJ. Tissue inhibitor of metalloproteinase-1 and interstitial collagenase expression in autoimmune chronic active hepatitis and activated human hepatic lipocytes. Clin Sci (Lond) 1995; 89: 75-81